The objective of this grant is to define at the cellular and molecular levels how the steroid hormone 1alpha,25 dihydroxyvitamin D3 [1a,25(OH)2D3] produces its biological responses. 1a,25(OH)2D3 is an unusually conformationally flexible molecule and consequently generates a wide array of molecular shapes that are available for binding to receptors. 1a,25(OH)2D3 generates biological responses via activation of at least two signal transduction pathways: (a) one shape of 1a,25(OH)2D3 interacts with a nuclear receptor [VDRnuc] to form a competent ligand-receptor partnership that, with other nuclear proteins, creates a transcription complex that regulates mRNA coding for selected proteins; and (b) a different shape of 1a,25(OH)2D3 interacts with a putative membrane [VDRmem] receptor to stimulate signal transduction events to activate raid responses [opening of Ca2+ and Cl- channels; activation of MAP-kinase; stimulation of intestinal Ca2+ transport or transcaltachia]. Functional analyses show that conformationally restricted analogs of 1 a,25(OH)2D3 VDRnuc and VDRmem bind distinctly different shapes of the hormone. Thus, the focus of the renewal of this 36-year grant is to define shapes of ligands and receptors for la,25(OH)D3 which will describe critical structure-function relationships between ligands (agonists and antagonists) and receptors.
Aim 1 : Using a 3D molecular model of the VDRnuc and site-directed mutagenesis in the ligand binding domain of VDRnuc, identify the specific amino acids that are critical for: (1.1) optimal ligand binding of the natural hormone 1a,25(OH)D3, and selected conformationally restricted agonist and potential antagonist analogs; and (1.2) formation of a complex between VDRnuc with the GRIP1 coactivator.
Aim 2 : Determine the shape of analogs of 1a,25(OH)2D3 which optimize their function as agonist or antagonist ligands for (2.1) the VDRnuc, and (2.2) the putative VDRmem.
Aim 3 ; For the signal transduction pathway(s) associated with 1a,25(OH)D3-mediated rapid responses: (3.1) Describe upstream pathways of MAP-kinase activation and resultant downstream consequences in the nucleus in human leukemic NB4 cells; (3.2) Determine whether 1a,25(OH)2D3 activates MAP kinase and/or alters gene expression in VDRnucK0 mice; and (3.3) Clone the putative VDRmem/binding protein for 1a,25(OH)2D3 found in chick intestinal basal lateral membranes. The long-term clinical goal is to use rational drug design to chemically synthesize agonist and antagonist analogs of 1 a,25(OH)2D3 to selectively interact with VDRnuc and VDRmem. This may allow specific therapeutic intervention (e.g. type 1 diabetes, leukemia cancer control, psoriasis, immune disorders or osteoporosis) without hypercalcemia.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
General Medicine B Study Section (GMB)
Program Officer
May, Michael K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Riverside
Schools of Earth Sciences/Natur
United States
Zip Code
Sequeira, Vanessa B; Rybchyn, Mark S; Tongkao-On, Wannit et al. (2012) The role of the vitamin D receptor and ERp57 in photoprotection by 1?,25-dihydroxyvitamin D3. Mol Endocrinol 26:574-82
Mizwicki, Mathew T; Menegaz, Danusa; Zhang, Jun et al. (2012) Genomic and nongenomic signaling induced by 1?,25(OH)2-vitamin D3 promotes the recovery of amyloid-? phagocytosis by Alzheimer's disease macrophages. J Alzheimers Dis 29:51-62
Menegaz, Danusa; Mizwicki, Mathew T; Barrientos-Duran, Antonio et al. (2011) Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). Mol Endocrinol 25:1289-300
Dixon, Katie M; Norman, Anthony W; Sequeira, Vanessa B et al. (2011) 1ýý,25(OH)ýýý-vitamin D and a nongenomic vitamin D analogue inhibit ultraviolet radiation-induced skin carcinogenesis. Cancer Prev Res (Phila) 4:1485-94
Mizwicki, Mathew T; Menegaz, Danusa; Yaghmaei, Sepideh et al. (2010) A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure-function implications. J Steroid Biochem Mol Biol 121:98-105
Norman, Anthony W; Bouillon, Roger (2010) Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood) 235:1034-45
Masoumi, Ava; Goldenson, Ben; Ghirmai, Senait et al. (2009) 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis 17:703-17
Bula, Craig M; Bishop, June E; Norman, Anthony W (2007) Conservative mutageneic perturbations of amino acids connecting helix 12 in the 1alpha,25(OH)2-D3 receptor (VDR) to the ligand cause significant transactivational effects. J Steroid Biochem Mol Biol 103:286-92
Norman, Anthony W; Bouillon, Roger; Whiting, Susan J et al. (2007) 13th Workshop consensus for vitamin D nutritional guidelines. J Steroid Biochem Mol Biol 103:204-5
Mizwicki, Mathew T; Bula, Craig M; Bishop, June E et al. (2007) New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model. J Steroid Biochem Mol Biol 103:243-62